Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
113.69
+0.60 (+0.53%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
73
74
Next >
Evaxion Biotech Partners With Merck To Expand Vaccine Development
September 26, 2024
Evaxion Biotech enters an expanded collaboration with Merck, granting an option to license preclinical vaccine candidates. The deal includes $3.2 million upfront and potential earnings up to $592...
Via
Benzinga
This Is What Whales Are Betting On Merck & Co
September 25, 2024
Via
Benzinga
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.
Via
Benzinga
Exposures
Product Safety
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
September 25, 2024
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and...
Via
Benzinga
Exposures
Product Safety
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
September 25, 2024
Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained...
Via
Benzinga
Merck & Co Unusual Options Activity For September 23
September 23, 2024
Via
Benzinga
Exploring NYSE:MRK's dividend characteristics.
September 20, 2024
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).
Via
Chartmill
Behind the Scenes of Merck & Co's Latest Options Trends
September 18, 2024
Via
Benzinga
Pfizer Advances On Its Cancer Journey
September 20, 2024
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...
Via
Benzinga
Is It Too Late to Buy ServiceNow Stock?
September 20, 2024
The stock is up nearly 60% since the beginning of the year.
Via
The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
September 18, 2024
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma.
Via
Benzinga
Exposures
Product Safety
NYSE:MRK: good value for what you're paying.
September 18, 2024
MERCK & CO. INC. (NYSE:MRK) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
Via
Benzinga
A Closer Look at 8 Analyst Recommendations For Merck & Co
September 16, 2024
Via
Benzinga
Where Will Merck Stock Be in 5 Years?
September 14, 2024
This drugmaker faces a key test in the next several years.
Via
The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
There's a lot of hope for ivonescimab, but are investors being a bit too bullish?
Via
The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.
Via
The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...
Via
Benzinga
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
September 16, 2024
NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1...
Via
Benzinga
Merck & Co Unusual Options Activity
September 13, 2024
Via
Benzinga
Merck Scores Two Key Victories With Keytruda In Women's Cancers
September 15, 2024
The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.
Via
Investor's Business Daily
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
September 13, 2024
Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028,...
Via
Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
September 13, 2024
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.
Via
Investor's Business Daily
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
September 12, 2024
The company is adding onto its success outperforming Merck's top drug in lung cancer patients.
Via
Investor's Business Daily
Is Summit Therapeutics a Buy Now?
September 10, 2024
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.
Via
The Motley Fool
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 09, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
73
74
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.